Abstract
Abstract Autophagy is increasingly an area of high potential therapeutic interest in hematopoietic malignancies, but its precise involvement in the control of leukemic cell growth and survival remain to be defined. We provide evidence that arsenic trioxide (As2O3) targets the BCR-ABL oncoprotein for degradation via autophagy, involving the p62/SQSTM1 and the protease cathepsin B. Utilizing either florescence probes or gold-conjugate antibodies we show co-localization of BCR-ABL and p62/SQSTM1 in autolysosomes. Also, by drug inhibition of either autophagy or cathepsin B, or by molecularly targeting p62/SQSMT1, Atg7 or cathepsin B, we documented reversal of the suppressive effect of As2O3 on BCR-ABL expressing cells, including primitive leukemic precursors from chronic myelogenous leukemia (CML) patients. Altogether, our data indicate that autophagy-induced degradation of BCR-ABL is critical for the generation of As2O3 antileukemic effects. These results raise the potential of targeting the autophagic machinery to enhance the antileukemic properties of arsenic trioxide on leukemia initiating stem cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr LB-81. doi:1538-7445.AM2012-LB-81
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
